Decreased intestinal CYP3A in celiac disease: Reversal after successful gluten-free diet: A potential source of interindividual variability in first-pass drug metabolism

Chim C. Lang, R. Michael Brown, Mark T. Kinirons, Mary Ann Deathridge, F. Peter Guengerich, Dermot Kelleher, D. Sean O'Briain, Fayez K Ghishan, Alastair J J Wood

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Background: Cytochrome P450 (CYP) 3A is constitutively expressed in human intestinal villi and may account for significant 'first-pass' prehepatic metabolism of a number of drugs in the intestine. Celiac discase results in small intestinal atrophy, We hypothesized that this would result in a loss of CYP3A. Methods: Formalin-fixed jejunal biopsy specimens taken from nine patients with celiac disease at variable times before and after treatment with a gluten-free diet were immunoperoxidase stained after incubation with anti-CYP3A4 rabbit antisera (1:2000 dilution). The amount of immunoreactive CYP3A was determined by two observers who were blinded to the treatment states of the patients, Staining intensity was graded on a numerical scale from 1 to 4+ on the basis of intensity of staining in individual enterocytes, as well as the total number of enterocytes stained. Results: Slides of biopsy specimens from all nine untreated patients with celiac disease were graded 1. Treatment with a gluten-free diet was associated with a significant increase in CYP3A immunoreactive protein in small bowel biopsy specimens (P < 0.05, Wilcoxon signed-rank test). Conclusions: We conclude that patients with celiac disease have low intestinal CYP3A immunoreactivity and that treatment with a gluten-free diet is associated with an increase in intestinal CYP3A immunoreactive protein. Our findings suggest that intestinal disease and variability in intestinal CYP3A activity might be an unexamined variable that may contribute to interindividual variability in drug disposition.

Original languageEnglish (US)
Pages (from-to)41-46
Number of pages6
JournalClinical Pharmacology and Therapeutics
Volume59
Issue number1
DOIs
StatePublished - Jan 1996
Externally publishedYes

Fingerprint

Gluten-Free Diet
Cytochrome P-450 CYP3A
Celiac Disease
Pharmaceutical Preparations
Enterocytes
Biopsy
Chymopapain
Staining and Labeling
Intestinal Diseases
Therapeutics
Nonparametric Statistics
Abdomen
Formaldehyde
Atrophy
Intestines
Immune Sera
Proteins
Rabbits

ASJC Scopus subject areas

  • Pharmacology

Cite this

Decreased intestinal CYP3A in celiac disease : Reversal after successful gluten-free diet: A potential source of interindividual variability in first-pass drug metabolism. / Lang, Chim C.; Brown, R. Michael; Kinirons, Mark T.; Deathridge, Mary Ann; Guengerich, F. Peter; Kelleher, Dermot; O'Briain, D. Sean; Ghishan, Fayez K; Wood, Alastair J J.

In: Clinical Pharmacology and Therapeutics, Vol. 59, No. 1, 01.1996, p. 41-46.

Research output: Contribution to journalArticle

Lang, Chim C. ; Brown, R. Michael ; Kinirons, Mark T. ; Deathridge, Mary Ann ; Guengerich, F. Peter ; Kelleher, Dermot ; O'Briain, D. Sean ; Ghishan, Fayez K ; Wood, Alastair J J. / Decreased intestinal CYP3A in celiac disease : Reversal after successful gluten-free diet: A potential source of interindividual variability in first-pass drug metabolism. In: Clinical Pharmacology and Therapeutics. 1996 ; Vol. 59, No. 1. pp. 41-46.
@article{8186535d54064bd9aa6a3da8438dfa04,
title = "Decreased intestinal CYP3A in celiac disease: Reversal after successful gluten-free diet: A potential source of interindividual variability in first-pass drug metabolism",
abstract = "Background: Cytochrome P450 (CYP) 3A is constitutively expressed in human intestinal villi and may account for significant 'first-pass' prehepatic metabolism of a number of drugs in the intestine. Celiac discase results in small intestinal atrophy, We hypothesized that this would result in a loss of CYP3A. Methods: Formalin-fixed jejunal biopsy specimens taken from nine patients with celiac disease at variable times before and after treatment with a gluten-free diet were immunoperoxidase stained after incubation with anti-CYP3A4 rabbit antisera (1:2000 dilution). The amount of immunoreactive CYP3A was determined by two observers who were blinded to the treatment states of the patients, Staining intensity was graded on a numerical scale from 1 to 4+ on the basis of intensity of staining in individual enterocytes, as well as the total number of enterocytes stained. Results: Slides of biopsy specimens from all nine untreated patients with celiac disease were graded 1. Treatment with a gluten-free diet was associated with a significant increase in CYP3A immunoreactive protein in small bowel biopsy specimens (P < 0.05, Wilcoxon signed-rank test). Conclusions: We conclude that patients with celiac disease have low intestinal CYP3A immunoreactivity and that treatment with a gluten-free diet is associated with an increase in intestinal CYP3A immunoreactive protein. Our findings suggest that intestinal disease and variability in intestinal CYP3A activity might be an unexamined variable that may contribute to interindividual variability in drug disposition.",
author = "Lang, {Chim C.} and Brown, {R. Michael} and Kinirons, {Mark T.} and Deathridge, {Mary Ann} and Guengerich, {F. Peter} and Dermot Kelleher and O'Briain, {D. Sean} and Ghishan, {Fayez K} and Wood, {Alastair J J}",
year = "1996",
month = "1",
doi = "10.1016/S0009-9236(96)90022-3",
language = "English (US)",
volume = "59",
pages = "41--46",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Decreased intestinal CYP3A in celiac disease

T2 - Reversal after successful gluten-free diet: A potential source of interindividual variability in first-pass drug metabolism

AU - Lang, Chim C.

AU - Brown, R. Michael

AU - Kinirons, Mark T.

AU - Deathridge, Mary Ann

AU - Guengerich, F. Peter

AU - Kelleher, Dermot

AU - O'Briain, D. Sean

AU - Ghishan, Fayez K

AU - Wood, Alastair J J

PY - 1996/1

Y1 - 1996/1

N2 - Background: Cytochrome P450 (CYP) 3A is constitutively expressed in human intestinal villi and may account for significant 'first-pass' prehepatic metabolism of a number of drugs in the intestine. Celiac discase results in small intestinal atrophy, We hypothesized that this would result in a loss of CYP3A. Methods: Formalin-fixed jejunal biopsy specimens taken from nine patients with celiac disease at variable times before and after treatment with a gluten-free diet were immunoperoxidase stained after incubation with anti-CYP3A4 rabbit antisera (1:2000 dilution). The amount of immunoreactive CYP3A was determined by two observers who were blinded to the treatment states of the patients, Staining intensity was graded on a numerical scale from 1 to 4+ on the basis of intensity of staining in individual enterocytes, as well as the total number of enterocytes stained. Results: Slides of biopsy specimens from all nine untreated patients with celiac disease were graded 1. Treatment with a gluten-free diet was associated with a significant increase in CYP3A immunoreactive protein in small bowel biopsy specimens (P < 0.05, Wilcoxon signed-rank test). Conclusions: We conclude that patients with celiac disease have low intestinal CYP3A immunoreactivity and that treatment with a gluten-free diet is associated with an increase in intestinal CYP3A immunoreactive protein. Our findings suggest that intestinal disease and variability in intestinal CYP3A activity might be an unexamined variable that may contribute to interindividual variability in drug disposition.

AB - Background: Cytochrome P450 (CYP) 3A is constitutively expressed in human intestinal villi and may account for significant 'first-pass' prehepatic metabolism of a number of drugs in the intestine. Celiac discase results in small intestinal atrophy, We hypothesized that this would result in a loss of CYP3A. Methods: Formalin-fixed jejunal biopsy specimens taken from nine patients with celiac disease at variable times before and after treatment with a gluten-free diet were immunoperoxidase stained after incubation with anti-CYP3A4 rabbit antisera (1:2000 dilution). The amount of immunoreactive CYP3A was determined by two observers who were blinded to the treatment states of the patients, Staining intensity was graded on a numerical scale from 1 to 4+ on the basis of intensity of staining in individual enterocytes, as well as the total number of enterocytes stained. Results: Slides of biopsy specimens from all nine untreated patients with celiac disease were graded 1. Treatment with a gluten-free diet was associated with a significant increase in CYP3A immunoreactive protein in small bowel biopsy specimens (P < 0.05, Wilcoxon signed-rank test). Conclusions: We conclude that patients with celiac disease have low intestinal CYP3A immunoreactivity and that treatment with a gluten-free diet is associated with an increase in intestinal CYP3A immunoreactive protein. Our findings suggest that intestinal disease and variability in intestinal CYP3A activity might be an unexamined variable that may contribute to interindividual variability in drug disposition.

UR - http://www.scopus.com/inward/record.url?scp=0030053064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030053064&partnerID=8YFLogxK

U2 - 10.1016/S0009-9236(96)90022-3

DO - 10.1016/S0009-9236(96)90022-3

M3 - Article

C2 - 8549032

AN - SCOPUS:0030053064

VL - 59

SP - 41

EP - 46

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 1

ER -